Fragment-Based Drug Discovery: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Paclitaxel in Apoptosis == | |||
<StructureSection load='1ysi' size='500' side='right' caption='Structure of HMG-CoA reductase (PDB entry [[1ysi]])' scene=''> | <StructureSection load='1ysi' size='500' side='right' caption='Structure of HMG-CoA reductase (PDB entry [[1ysi]])' scene=''> | ||
This represents the binding of the anti-cancer drug, paclitaxel, to the anti-apoptotic protein, Bcl-xl. The protein includes seven <scene name='Sandbox_reserved_394/Alpha_helices/1'>alpha helices</scene> and no beta sheets. | This represents the binding of the anti-cancer drug, paclitaxel, to the anti-apoptotic protein, Bcl-xl. The protein includes seven <scene name='Sandbox_reserved_394/Alpha_helices/1'>alpha helices</scene> and no beta sheets. | ||
Bcl-xl is a protein that is over-expressed in many forms of cancers and is an initiator of tumor formation. There is also evidence that Bcl-xl expression may also contribute to chemo-resistance. Paclitaxel has been show to effectively inhibit the over-expression of this protein thereby inducing tumor regression and increasing chemo-sensitivity. | Bcl-xl is a protein that is over-expressed in many forms of cancers and is an initiator of tumor formation.<ref>Oltersdorf T., Elmore S.W., Shoemaker A.R. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Vol 435|2 June 2005|doi:10.1038/nature03579</ref> There is also evidence that Bcl-xl expression may also contribute to chemo-resistance. Paclitaxel has been show to effectively inhibit the over-expression of this protein thereby inducing tumor regression and increasing chemo-sensitivity. | ||
| Line 24: | Line 24: | ||
| align="center" | <scene name='Sandbox_reserved_394/Phe109_and_ala108/1'>Ala108</scene> || align="center" | <scene name='Sandbox_reserved_394/Tyrosine_105/1'>Tyr105</scene> || align="center" | <scene name='Sandbox_reserved_394/Phe_101/1'>Phe101</scene> || align="center" | <scene name='Sandbox_reserved_394/Glycine_142/1'>Gly142</scene> | | align="center" | <scene name='Sandbox_reserved_394/Phe109_and_ala108/1'>Ala108</scene> || align="center" | <scene name='Sandbox_reserved_394/Tyrosine_105/1'>Tyr105</scene> || align="center" | <scene name='Sandbox_reserved_394/Phe_101/1'>Phe101</scene> || align="center" | <scene name='Sandbox_reserved_394/Glycine_142/1'>Gly142</scene> | ||
|} | |} | ||
</StructureSection> | </StructureSection> | ||
== References == | |||
{{Reflist}} | |||
Revision as of 21:36, 26 September 2012
Paclitaxel in ApoptosisPaclitaxel in Apoptosis
This represents the binding of the anti-cancer drug, paclitaxel, to the anti-apoptotic protein, Bcl-xl. The protein includes seven and no beta sheets.
Bcl-xl is a protein that is over-expressed in many forms of cancers and is an initiator of tumor formation.[1] There is also evidence that Bcl-xl expression may also contribute to chemo-resistance. Paclitaxel has been show to effectively inhibit the over-expression of this protein thereby inducing tumor regression and increasing chemo-sensitivity.
Shown here is the interaction between paclitaxel and the protein via . The hydrogen bond is formed between an oxygen from the sulfoxone portion of the drug to an "N-H" group of a glycine amino acid. This forms one of the intermolecular or "weak" bonds between the drug and protein.
Shown here is a sort of formed between the protein (red) and hydrophobic, or "water hating", portions of paclitaxel. This is an example of hydrophobic bonding formed by intermolecular forces between some hydrophobic sections of the protein with hydrophobic portions of the ligand.
Click on each amino acid to view the hydrophobic interactions with the ligand:
|
| ||||||||||||||||||
ReferencesReferences
- ↑ Oltersdorf T., Elmore S.W., Shoemaker A.R. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Vol 435|2 June 2005|doi:10.1038/nature03579